4th Quarter - Report

BIOCOM for BIOCOM

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Address issues related to patent reform legislation implementation, including support for fee retention

LobbyistCovered position, as disclosed
MADELEINE BAUDOIN —
JOE PANETTA —

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Addressed concerns over Mobile Medical Applications Addressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period Discussed the Medical Device Regulatory Improvement Act 10 House Bills which include the following: oH.R. 3209, Premarket Predictability Act of 2011 oH.R. 3203, Novel Device Regulatory Relief Act of 2011 oH.R. 3230, Keeping America Competitive through Harmonization Act oH.R. 3205, FDA Renewing Efficiency from Outside Review Management Act oH.R. 3211, Humanitarian Device Reform Act oH.R. 3208, Patients Come First Act oH.R 3206,Cultivating Scientific Expertise to Foster Innovation Act oH.R. 3214, Food and Drug Administration Mission Reform Act oH.R. 3207, Modernizing Laboratory Test Standards for Patients Act oH.R. 3204, Guidance Accountability and Transparency Act

LobbyistCovered position, as disclosed
MADELEINE BAUDOIN —
JOE PANETTA —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)

Taxation/Internal Revenue Code TAX

Voiced support HR 2632, the Life Science Jobs and Investment Act

LobbyistCovered position, as disclosed
MADELEINE BAUDOIN —
JOE PANETTA —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)

Bills named: H.R. 2632 (112th)

Medicare/Medicaid MMM

Opposed proposed cuts to Part B, which provides oncology products for administration in physicians offices

LobbyistCovered position, as disclosed
MADELEINE BAUDOIN —
JOE PANETTA —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.